Compare Merck & Co., Inc. (MRK) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Williams Companies Inc — how do they compare? Merck & Co., Inc. trades at $133.58 (market cap $321.77B), while Williams Companies Inc trades at $73.54 (market cap $88.45B). The key difference: Merck & Co., Inc. is far larger — about 3.6× Williams Companies Inc's market cap, and Williams Companies Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| MRK | WMB | |
|---|---|---|
Market Cap | $321.77B | $88.45B |
Sector | Health | Energy |
52-Week High | $131.84 | $79.40 |
52-Week Low | $77.60 | $56.51 |
Enterprise Value | $368.53B | $119.07B |
Dividend Yield | 2.61% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
WMB trades at $73.72, up 2.6% today, with a bullish technical signal and strong analyst support. The company reported mixed quarterly earnings but raised full-year EBITDA guidance to $8.4 billion following its $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast footprint. Fundamentals show robust profitability with a 25.18% net income margin and 24.02% ROE, though valuation multiples like a P/E of 28.81 appear elevated.
The outlook is positive, driven by growth initiatives and stable cash flows, but risks include execution of the large acquisition and sensitivity to energy demand. With a consensus price target of $87.14 implying 18% upside, the stock offers growth potential tempered by integration challenges and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
